company background image
ABSI

AbsciNasdaqGS:ABSI Stock Report

Last Price

US$6.64

Market Cap

US$614.8m

7D

0.5%

1Y

n/a

Updated

25 Jan, 2022

Data

Company Financials +
ABSI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ABSI Stock Overview

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Absci
Historical stock prices
Current Share PriceUS$6.64
52 Week HighUS$31.53
52 Week LowUS$6.12
Beta0
1 Month Change-23.41%
3 Month Change-51.99%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-69.25%

Recent News & Updates

Jan 10

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from >$2bn, to $665m at the time of writing. This isn't unusual for a drug discoverer/developer - Abcellera, also based in Vancouver, has seen its stock fall >80% while even Ginkgo Bioworks stock is -30% since IPO. Absci has recently announced a partnership with Merck for up to three candidates which could be worth up to $640m, if all milestones are met. That's not necessarily likely but it does serve as validation of the young company's technology and approach. Merck is revamping its R&D and Absci could make itself an indispensable part of that. The deal will not do much for Merck in the short term, but it may help push Absci's valuation higher - shares were 44%-plus on the news. Investing with a five-year investment horizon may offer a good ROI.

Jul 22

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today. CEO Sean McClain discusses the emotion around going public, acquisitions in the time of Covid and being a technology driven company. Providing tech solutions for pharma partners and what metric is key to watch over the next year.

Shareholder Returns

ABSIUS Life SciencesUS Market
7D0.5%-4.5%-5.8%
1Yn/a2.0%4.2%

Return vs Industry: Insufficient data to determine how ABSI performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how ABSI performed against the US Market.

Price Volatility

Is ABSI's price volatile compared to industry and market?
ABSI volatility
ABSI Average Weekly Movement14.0%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: ABSI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ABSI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011207Sean McClainhttps://www.absci.com

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Fundamentals Summary

How do Absci's earnings and revenue compare to its market cap?
ABSI fundamental statistics
Market CapUS$614.81m
Earnings (TTM)-US$83.80m
Revenue (TTM)US$6.06m

101.5x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABSI income statement (TTM)
RevenueUS$6.06m
Cost of RevenueUS$33.42m
Gross Profit-US$27.36m
ExpensesUS$56.44m
Earnings-US$83.80m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.91
Gross Margin-451.62%
Net Profit Margin-1,383.25%
Debt/Equity Ratio1.1%

How did ABSI perform over the long term?

See historical performance and comparison

Valuation

Is Absci undervalued compared to its fair value and its price relative to the market?

1.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABSI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABSI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABSI is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: ABSI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABSI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABSI is good value based on its PB Ratio (1.6x) compared to the US Life Sciences industry average (3.2x).


Future Growth

How is Absci forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

1.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABSI's revenue (51.6% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ABSI's revenue (51.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ABSI is forecast to be unprofitable in 3 years.


Past Performance

How has Absci performed over the past 5 years?

-94.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ABSI is currently unprofitable.

Growing Profit Margin: ABSI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ABSI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ABSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABSI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).


Return on Equity

High ROE: ABSI has a negative Return on Equity (-20.81%), as it is currently unprofitable.


Financial Health

How is Absci's financial position?


Financial Position Analysis

Short Term Liabilities: ABSI's short term assets ($300.7M) exceed its short term liabilities ($30.2M).

Long Term Liabilities: ABSI's short term assets ($300.7M) exceed its long term liabilities ($30.9M).


Debt to Equity History and Analysis

Debt Level: ABSI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ABSI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABSI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ABSI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 103.1% each year


Dividend

What is Absci current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Sean McClain (31 yo)

10.42yrs

Tenure

US$1,180,884

Compensation

Mr. Sean Mcclain is the Founder of Absci Corporation (formerly known as AbSci, LLC) and serves as its Chief Executive Officer since August 2011 and Director since its formation in October 2020. Mr. Mcclain...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD1.18M) is below average for companies of similar size in the US market ($USD2.39M).

Compensation vs Earnings: Insufficient data to compare Sean's compensation with company performance.


Leadership Team

Experienced Management: ABSI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: ABSI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ABSI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ABSI only recently listed within the past 12 months.


Top Shareholders

Company Information

Absci Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Absci Corporation
  • Ticker: ABSI
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$614.807m
  • Shares outstanding: 92.59m
  • Website: https://www.absci.com

Number of Employees


Location

  • Absci Corporation
  • 18105 SE Mill Plain Boulevard
  • Vancouver
  • Washington
  • 98683
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/25 06:39
End of Day Share Price2022/01/24 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.